about
Gene therapy for the inner earInner ear symptoms and disease: pathophysiological understanding and therapeutic optionsSustained release of triamcinolone acetonide from an intratympanically applied hydrogel designed for the delivery of high glucocorticoid doses.Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies.Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness.Bovine serum albumin nanoparticles as controlled release carrier for local drug delivery to the inner ear.Gene therapy for deafness.Current status and prospects of gene therapy for the inner earIntracochlear drug delivery systems.The design and screening of drugs to prevent acquired sensorineural hearing lossDistribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation.Kinetics of reciprocating drug delivery to the inner earBiomaterials in cochlear implants.Localized cell and drug delivery for auditory prostheses.Drug delivery for treatment of inner ear disease: current state of knowledgePrinciples of local drug delivery to the inner ear.Current advances in research and clinical applications of PLGA-based nanotechnology.Inner ear drug delivery for auditory applications.Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules.Drug delivery to the ear.Enhanced local bioavailability of single or compound drugs delivery to the inner ear through application of PLGA nanoparticles via round window administration.A novel chitosan-hydrogel-based nanoparticle delivery system for local inner ear application.Drug delivery systems for the treatment of sensorineural hearing loss.Reservoir-based polymer drug delivery systems.Gene transfer in inner ear cells: a challenging race.Polyamidoamine dendrimers as gene delivery carriers in the inner ear: How to improve transfection efficiency.Nanomedicine strategies for drug delivery to the ear.Nanotechnology and the treatment of inner ear diseases.A novel vehicle for local protein delivery to the inner ear: injectable and biodegradable thermosensitive hydrogel loaded with PLGA nanoparticles.Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss.The effect of surface charge of glycerol monooleate-based nanoparticles on the round window membrane permeability and cochlear distribution.Innovative pharmaceutical approaches for the management of inner ear disorders.Emerging Gene Therapies for Genetic Hearing Loss.Dexamethasone levels and base-to-apex concentration gradients in the scala tympani perilymph after intracochlear delivery in the guinea pig.A microfluidic reciprocating intracochlear drug delivery system with reservoir and active dose control.Simulation of application strategies for local drug delivery to the inner ear.Stealth-nanoparticle strategy for enhancing the efficacy of steroids in mice with noise-induced hearing loss.Inner ear drug delivery system from the clinical point of view.Principles of inner ear sustained release following intratympanic administration.Distribution of PLGA nanoparticles in chinchilla cochleae.
P2860
Q26851920-6F7E7F2D-9245-48D0-9875-5C9E47CB68ABQ26997318-52B828AD-7E8B-4BBB-90A4-62F19679ECF3Q30392675-D7F4309C-9EEF-4E17-BF48-99A2C4482505Q30409983-563C5584-B14E-4807-B7AC-8BAEA0E91920Q30411312-C3185D94-66B6-44DF-8E73-7D0F6EC81637Q30433180-8B937584-8602-4873-9778-31FEBBBF82C3Q30434063-E6265FCB-BB01-4718-98C2-5CD0F4043AA8Q30461494-E83AB72F-F57F-4BE3-8A55-0E08FEE4B9CCQ30464082-5F8C039C-4D47-4D21-958E-7211F8A89C4CQ30465748-E76F9CF4-E8CE-45A1-9648-CB46C9713900Q30466045-62CA6701-A696-44C5-BE50-AAF324E58DCDQ30466728-B1D19343-BFF0-4175-9579-195BA5B1FCBFQ30472996-CC9D927C-02A4-49F7-86A3-62976D14140CQ30475885-82804294-6C7A-49B3-B7C1-D234603F3BA4Q30476020-3A13CC95-78AD-4D7D-A2E3-F4780BFBD05CQ30478838-1033B469-4E04-4BCA-B119-E9432064F422Q30482916-EC249228-0ECF-4379-9AB6-6B9BF0545195Q30484636-F1F2D577-53D4-4154-A8ED-07739C3F1EC9Q33491736-900245FC-8B4D-467D-8793-40713669DF16Q34549540-D266FE3B-E5A0-4ABD-B30C-1F92A49E3F34Q34637830-A7C3B457-C644-4C3A-888A-8E1BA0E7E030Q35193795-49DBB072-A357-46C2-BA1C-9852E9DD2EC1Q36799313-82862A33-96D0-482D-87FA-8C3022282CF8Q37987369-6C3EAFCB-CB78-4874-BB5D-5652E62C7C0AQ38022141-096A2111-4B61-4797-8501-B7308FE70D4CQ38043458-861304D4-AF15-4699-8125-52254A05F011Q38120319-28D795FF-ECD8-4A36-A166-0E6FE4573915Q38264388-9F746A60-C3B7-4DFA-897F-94479658DFBFQ38603485-D3AC4FD7-3D61-49DC-8E6F-A199370F27BBQ38706405-58933F85-CC4F-462B-BB67-CF13FB5CFDAFQ39110356-0D327E7B-87B8-491C-B18F-E2E25CF6D4BEQ39277413-1900A6A2-CAA2-413C-8EB2-6C03FD73787CQ40080564-19E27E16-CA37-49E7-8278-066A5290372CQ41810387-34EF3FA8-B2AA-4A21-ACB0-9717DB5789B3Q41891299-8BCA07B0-F12E-4705-BDE4-09DE6E702569Q41938982-064C1733-C003-4032-A3AE-AB3884319132Q42786617-1E84A2A9-D856-4154-BC0C-6AE472E7EDD2Q42873726-30DE1DE6-0D15-4584-A9C9-E5742726656FQ46652572-986357BB-2713-4B3F-BB07-A76485C77E61Q46975990-E54EDEC0-59AF-45C6-B70B-31896E2A6A43
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Drug delivery to the cochlea using PLGA nanoparticles.
@en
Drug delivery to the cochlea using PLGA nanoparticles.
@nl
type
label
Drug delivery to the cochlea using PLGA nanoparticles.
@en
Drug delivery to the cochlea using PLGA nanoparticles.
@nl
prefLabel
Drug delivery to the cochlea using PLGA nanoparticles.
@en
Drug delivery to the cochlea using PLGA nanoparticles.
@nl
P2093
P1433
P1476
Drug delivery to the cochlea using PLGA nanoparticles.
@en
P2093
Juichi Ito
Megumu Higaki
Tae-Soo Kim
Takayuki Nakagawa
Tetsuya Tamura
Tomoko Kita
Tsutomu Ishihara
Tsuyoshi Endo
Yutaka Mizushima
P2860
P304
P356
10.1097/01.MLG.0000180174.81036.5A
P407
P577
2005-11-01T00:00:00Z